2.
Guidelines for the management of oesophageal and gastric cancer
by Allum, William H
Gut, 2011-11, Vol.60 (11), p.1449-2
3.
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers
by van der Post, Rachel S
Journal of Medical Genetics, 2015-06, Vol.52 (6), p.361-374
4.
Gastric cancer
by Van Cutsem, Eric, Prof
The Lancet (British edition), 2016, Vol.388 (10060), p.2654-2664
5.
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
by Bang, Yung-Jue, Prof
The Lancet (British edition), 2012, Vol.379 (9813), p.315-321
6.
Gastric cancer
by Hartgrink, Henk H, MD
The Lancet (British edition), 2009, Vol.374 (9688), p.477-490
7.
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
by Kim, Seung Tae
Nature medicine, 2018-09, Vol.24 (9), p.1449-1458
8.
9.
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
by Fujitani, Kazumasa, MD
The lancet oncology, 2016, Vol.17 (3), p.309-318
10.
Management of gastric cancer in Asia: resource-stratified guidelines
by Shen, Lin, Prof
The lancet oncology, 2013, Vol.14 (12), p.e535-e547
11.
MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome
by Wang, Kunning Kunning
Gut, 2015-07-23, Vol.65 (10), p.1619-1631
12.
Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pathway for gastric cancer metastasis
by Hao, Ning-Bo
Cancer letters, 2015, Vol.361 (1), p.57-66
13.
Helicobacter pylori -induced gastric inflammation and gastric cancer
by Wang, Fei
Cancer letters, 2013, Vol.345 (2), p.196-202
14.
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, dou...
by Catenacci, Daniel V T
The lancet oncology, 2017-11, Vol.18 (11), p.1467-1482
15.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gas...
by Doi, Toshihiko
The lancet oncology, 2017-11, Vol.18 (11), p.1512-1522
16.
Early or late antibiotic intervention prevents Helicobacter pylori -induced gastric cancer in a mouse model
by Zhang, Songhua
Cancer letters, 2014, Vol.355 (1), p.106-112
17.
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, place...
by Tabernero, Josep
The lancet oncology, 2018-10, Vol.19 (10), p.1372-1384
18.
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
by Gómez-Martin, Carlos
Journal of Clinical Pathology, 2012-08, Vol.65 (8), p.751-757
19.
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
by Lin, Suling J
Gut, 2015-11, Vol.64 (11), p.1721-1731
20.
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
by Muro, Kei, Dr
The lancet oncology, 2016, Vol.17 (6), p.717-726
